InventorsTimo Heinrich, Henning Böttcher, Kai Schiemann, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Hartmut Greiner, Christoph Seyfried, Michel Brunet, Jean Zeiller, Jean Berthelon
Benzodioxepines of the formula (I) and physiologically tolerated salts and solvates thereof, in which R1, R2, R3, R4, A, B, a and b have the meanings indicated in claim 1, are ligands of the 5HT1A receptors and/or the 5HT4 receptors with simultaneously strong serotonin reuptake inhibition. They can be employed for the treatment and prophylaxis of various diseases
Drawings
Claims20
A benzodioxepine compound of formula I
in which
R1 are, each independently of one another, alkyl, (CH2)mOD, (CH2)mCN, (CH2)mCOR5 or (CH2)mCH2R5,
m is 0 or 1,
R2, R3 are, each independently of one another, H, or alkyl having 1 to 5 C atoms,
R4 are, each independently of one another, alkyl having 1 to 5 C atoms, heteroalkyl having 1 to 5 C atoms, alkoxy having 1 to 5 C atoms, alkoxyalkyl having 2 to 5 C atoms, Hal, CN, COR5 or OH,
R5 stands for OD, NH2, NHD or ND2,
A stands for CnH2n,
n is 2, 3, or 4,
B stands for CpH2p,
p is 0, 1, 2, 3 or 4,
D are, each independently of one another, H, alkyl having 1 to 5 C atoms, alkoxyalkyl having 2 to 5 C atoms, aryl or aralkyl
a, b stand for 0, 1 or 2, and
Hal stands for F, Cl, Br or I,
or a pharmaceutically acceptable salt or solvate thereof.
#The invention relates to substituted benzodioxepines of the formula I
#in which R1, independently of one another, is selected from alkyl, (CH2)mOD, (CH2)mCN, (CH2)mCOR5 or (CH2)mCH2R5, where m=0 or 1 R2, R3, independently of one another, is selected from H, alkyl having 1 to 5 C atoms, R4, independently of one another, is selected from alkyl having 1 to 5 C atoms, heteroalkyl having 1 to 5 C atoms, alkoxy having 1 to 5 C atoms, alkoxyalkyl having 2 to 5 C atoms, Hal, CN, COR5 or OH, R5 stands for OD, NH2, NHD or ND2, A stands for CnH2n where n=2, 3, or 4, B stands for CpH2p where p=0, 1, 2, 3 or 4, D, independently of one another, is selected from H, alkyl having 1 to 5 C atoms, alkoxyalkyl having 2 to 5 C atoms, aryl or aralkyl, a, b stand for 0, 1 or 2 and Hal stands for F, Cl, Br or I, and physiologically tolerated salts and solvates thereof.
#Substituted benzodioxepines and the use thereof as pharmaceutical active ingredients for the treatment of hypertension are described, for example, in DE 2847623, BE 613210, BE 613212 and BE 613215.
Detailed description942 words
#The synthesis of the starting material used here is known from the literature (Sci. Pharm. 201, 69(1), 11-20).
#4 g (24 mmol) of benzo[b]-1,4-dioxepin-3-one and 5.2 g (24 mmol) of 3-(4-aminobutyl)-1H-5-indolecarbonitrile are dissolved in 270 ml of methanol and refluxed for 2 h. After the batch has been cooled to 10° C., 1.4 g (36 mmol) of sodium borohydride are added in portions, and, after one hour, the mixture is refluxed for one hour. The batch is evaporated to dryness and taken up in ethyl acetate.
#After washing with water and drying using magnesium sulfate, the residue is chromatographed over a silica-gel column using a 7:3 mixture of ethyl acetate and isopropanol, giving 1.86 g (16%) of N-(3,4-dihydro-2H-1,5-benzodioxepin-3-yl)-4-(5-cyano-3-indole)butylamine.
Application
10/539,515Filed 27 Nov 2003
Priority
EP 0202859620 Dec 2002
Published
US 2006/0167078 A127 Jul 2006
Granted
7 Aug 2007
Term ended
14 Jul 2024Estimated · howhide20 years from earliest known nonprovisional domestic filing plus recorded patent term adjustment, including 230 days of adjustment. Maintenance-fee lapses, terminal disclaimers and statutory extensions have not been checked. The continuity chain may be incomplete; this is not an enforceability determination.